A Phase 1 Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs TAS 114 (Primary) ; Gimeracil/oteracil/tegafur
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical Company
- 02 Aug 2017 Status changed from active, no longer recruiting to completed.
- 06 Feb 2017 Planned End Date changed from 1 Oct 2016 to 1 Aug 2017.
- 06 Feb 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2017.